Pharmaceutical firm Cytogen reported second-quarter revenues of $2.8 million, up 16% from the $2.4 million posted in the same period last year. For the quarter (end-June 30), the Princeton, NJ-based vendor had a net loss of $3.1 million, compared with a net loss of $2.4 million in the second quarter of 2000. Among the bright spots, product sales from OncoScint, ProstaScint, and BrachySeed turned in revenues of $2 million, up 22% from the $1.6 million posted in the second quarter of 2000.
By AuntMinnie.com staff writersAugust 7, 2001
Related Reading
DraxImage gets clearance for palladium version of BrachySeed, June 28, 2001
Cytogen builds executive team, June 11, 2001
Cytogen turns in revenue gains, April 27, 2001
ProstaScint scans predict prostate cancer recurrence and metastases, January 31, 2001
Draxis signs brachytherapy seed agreement with Cytogen, September 14, 2000
Copyright © 2001 AuntMinnie.com
